The US Food and Drug Administration (FDA) has accepted to review Regeneron Pharmaceuticals’ resubmitted biologics license application (BLA) for linvoseltamab to treat adults with relapsed/refractory (R/R) multiple myeloma (MM).
Radiopharmaceutical company AdvanCell has expanded its partnership with Eli Lilly and Company to advance targeted alpha therapies for the treatment of cancer.
Norgine Pharmaceuticals has launched Pedmarqsi (sodium thiosulfate injection) commercially in Germany.
Essential Pharma and Clinigen have announced their Japan-Asia Pacific (JAPAC) collaboration expansion to improve patient access to four therapies in Korea and Japan.
DEBRA Research and LEO Pharma have announced a non-exclusive strategic collaboration aiming to improve scouting capabilities and offer extra capacity to propel the development of therapies for Epidermolysis Bullosa (EB).
The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of Auron Therapeutics’ oral KAT2A/B degrader, AUTX-703, allowing it to progress through clinical development for haematological malignancies.
BioNTech has completed the previously announced acquisition of biotechnology company Biotheus for $800m, a move that strengthens its oncology strategy.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC) in adults.
Rad AI has raised an oversubscribed $60m in a Series C funding round to expedite the development and deployment of generative AI technology to healthcare providers and systems across the globe.
Scholar Rock has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for muscle-targeted therapy, apitegromab, aimed at enhancing motor function in individuals with spinal muscular atrophy (SMA) who are already on SMN-targeted therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.